Syndax reports FY2023 net loss $209.4M; axatilimab PDUFA Aug 28, 2024; cash $600M through 2026

Syndax Pharmaceuticals Inc

2023-FY EPS reported -$2.98

Net loss for FY2023: $209.4M ($2.98 per share) vs $149.3M ($2.46 per share) in 2022.
Cash and investments: $600.5M as of Dec 31, 2023, expected to fund operations through 2026.
BLA for axatilimab in chronic GVHD granted Priority Review; PDUFA date Aug 28, 2024.
NDA for revumenib in R/R KMT2Ar acute leukemia submitted under RTOR; PDUFA date expected 1Q24.
Enrollment in AUGMENT-101 mNPM1 cohort to complete late 1Q/early 2Q; topline data in 4Q24.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Syndax Pharmaceuticals Inc reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 27, 2024, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0000950170-24-021086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.